Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 22INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 13Other solid neoplasm 6Head & Neck 4Breast 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × Gynecologic × Clear all
NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
194 enrolled
Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡